News | Heart Valve Technology | January 04, 2024

Henry Ford Health Cardiologists Publish Case Series Study on Heart Valve Procedure

Procedure shows promise for treating severely calcified mitral valve stenosis

Study investigators Drs. Pedro Engel-Gonzalez and Gennaro Giustino from Henry Ford Health.

Study investigators Drs. Pedro Engel-Gonzalez and Gennaro Giustino from Henry Ford Health. Image courtesy of Hentry Ford Health


January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart Disease team show that severe mitral stenosis, due to a build-up of calcium deposits in the mitral valve common in elderly patients, can be safely and successfully treated using Intravascular lithotripsy (IVL)-enabled percutaneous balloon mitral valvuloplasty. However, larger prospective studies in high-risk population are needed to confirm the findings.

These key takeaways from the research letter on IVL-facilitated valvuloplasty for severely calcified mitral valve stenosis are published in the Journal of the American College of Cardiology (JACC) Cardiovascular Interventions.

"We’ve developed a new strategy to treat our patients in the Detroit community and beyond," said corresponding author Pedro Engel Gonzalez, M.D., an interventional cardiologist and structural heart disease expert at Henry Ford Health. “We are looking forward to treating patients who have no other options for mitral stenosis diseased valves.”

IVL is a novel approach to lesion preparation of severely calcified plaques in coronary and peripheral vessels. Lithotripsy is delivered by vaporizing fluid to create an expanding bubble that generates sonic pressure waves that interact with arterial calcification.

In patients with severe mitral stenosis—which is the narrowing of the valve between the two left heart chambers that is a chronic degenerative process—who are not suitable for surgery or other transcatheter options, the IVL valvuloplasty is a possible option.

The Henry Ford team performed its first IVL-enabled mitral valvuloplasty back in 2019 and completed its first published case study. Now, the team has published its first case series report on the safety and efficacy of this procedure based on the 24 cases that have been performed so far.

The safety and efficacy results have Dr. Engel Gonzalez and the research team feeling very optimistic about the availability of this procedure to more patients going forward.

The research letter’s lead author, Gennaro Giustino, M.D., a Structural Heart Disease Fellow at Henry Ford Hospital, is also optimistic that these findings will lead to helping more people. “Patients with severely calcified mitral stenosis are often not candidates for conventional open-heart surgery,” said Dr. Giustino. “This minimally invasive technique pioneered at Henry Ford is a promising and safe treatment option for these patients to improve their cardiac symptoms and quality of life."

For more information: https://www.henryford.com/


Related Content

News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
Subscribe Now